Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06613191
PHASE4

Colonoscopy and Antiplatelet Therapy Trial

Sponsor: Ochsner Health System

View on ClinicalTrials.gov

Summary

Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.

Official title: P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy

Key Details

Gender

All

Age Range

45 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-10-01

Completion Date

2026-06-30

Last Updated

2024-09-25

Healthy Volunteers

No

Interventions

DRUG

Aspirin

Participant will be on aspirin alone or P2Y12 inhibitor alone

DRUG

P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)

Participant will be taking either P2Y12 inhibitor at time of colonoscopy

Locations (1)

Ochsner Health

New Orleans, Louisiana, United States